--- title: "Agape ATP | 10-K: FY2025 Revenue: USD 1.524 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/282547530.md" datetime: "2026-04-13T12:51:57.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282547530.md) - [en](https://longbridge.com/en/news/282547530.md) - [zh-HK](https://longbridge.com/zh-HK/news/282547530.md) --- # Agape ATP | 10-K: FY2025 Revenue: USD 1.524 M Revenue: As of FY2025, the actual value is USD 1.524 M. EPS: As of FY2025, the actual value is USD -2.85. EBIT: As of FY2025, the actual value is USD -3.26 M. #### Segment Revenue - **Total Revenue**: Agape ATP Corporation generated $1,524,262 in total revenue for the year ended December 31, 2025, an increase of approximately 15.2% from $1,322,747 in 2024. - **Network Marketing Business**: Revenue decreased by $65,774, or approximately 48.0%, from $137,050 (10.4% of total revenue) in 2024 to $71,276 (4.7% of total revenue) in 2025, attributed to a limited product range and a strategic shift in business focus. - **Complementary Health Therapies**: Revenue decreased by $39,305, or approximately 3.5%, from $1,120,843 (84.7% of total revenue) in 2024 to $1,081,538 (71.0% of total revenue) in 2025, due to lower revenue from overseas customers. - **Wellness and Wellbeing Lifestyle**: Revenue significantly increased by $209,630, or approximately 948.9%, from $22,091 (1.7% of total revenue) in 2024 to $231,721 (15.2% of total revenue) in 2025, driven by digital advertisement campaigns and marketing activities for skin care and healthcare products. - **Green Energy**: Revenue increased by $96,964, or approximately 226.7%, from $42,763 (3.2% of total revenue) in 2024 to $139,727 (9.1% of total revenue) in 2025. #### Operational Metrics - **Net Loss Attributable to Agape ATP Corporation**: The company reported a net loss of - $2,279,791 for 2025, compared to - $2,470,474 for 2024, representing a decrease in loss of approximately 7.2%. - **Gross Profit**: Gross profit was $838,270 in 2025 (gross margin of 55.0%) compared to $759,148 in 2024 (gross margin of 57.4%). The decrease in gross profit margin in 2025 was due to the low gross profit margin in green energy. - **Segment Gross Profit Margin**: - Network marketing business: 58.8% in 2025 and 69.6% in 2024. - Complementary health therapies: 55.1% in 2025 and 59.1% in 2024. - Wellness and wellbeing lifestyle: 84.3% in 2025 and 2.3% in 2024. - Green energy: 3.4% in 2025 and 2.9% in 2024. - **Operating Expenses**: Total operating expenses increased by $762,426 from - $3,332,491 in 2024 to - $4,094,917 in 2025. - **Selling Expenses**: Increased by $79,362 (48.8%) to $242,074 in 2025 from $162,712 in 2024, primarily due to increased promotional expenses for wellness and wellbeing lifestyle operations. - **Commission Expenses**: Significantly increased by $38,786 (111.1%) to $73,691 in 2025 from $34,905 in 2024, driven by increased revenue from wellness and wellbeing lifestyle operations. - **General and Administrative Expenses**: Increased by $644,278 (20.6%) to $3,779,152 in 2025 from $3,134,874 in 2024, mainly due to an increase in professional fees. - **Loss from Operations**: The loss from operations was - $3,256,647 in 2025, compared to - $2,573,343 in 2024. - **Other Income, Net**: Total other income, net, significantly increased to $951,325 in 2025 from $92,233 in 2024, largely due to an exchange gain, net, of $826,149 in 2025. - **Inventory Write-off/Write-down**: Inventory write-downs were $11,825 in 2025 and $7,081 in 2024. Inventory write-offs were $7,035 in 2025 and $0 in 2024. - **Allowance for Credit Loss**: The company recognized an allowance for credit loss of $519,442 in 2025 and $98,705 in 2024. #### Cash Flow - **Net Cash Used in Operating Activities**: - $2,413,422 in 2025, compared to - $2,726,215 in 2024. - **Net Cash Used in Investing Activities**: - $23,001,049 in 2025, primarily due to advances for investment, compared to - $50,050 in 2024. - **Net Cash Provided by Financing Activities**: $23,498,646 in 2025, mainly from proceeds from the issuance of common stock ($23,000,000) and advances from a director ($520,831), compared to net cash used of - $11,856 in 2024. #### Unique Metrics - **Customer Deposits**: $168,603 as of December 31, 2025, compared to $96,976 as of December 31, 2024. - **Prepayments and Deposits**: $24,077,559 as of December 31, 2025, including a $23,816,398 deposit for investment with Bi Cheng Investment Management Limited, compared to $586,172 as of December 31, 2024. - **Amounts Held in eWallets**: $189,063 as of December 31, 2025, compared to $173,995 as of December 31, 2024. #### Outlook / Guidance Agape ATP Corporation’s liquidity for the next twelve months is expected to be supported by anticipated cash flows from operating activities and cash on hand. Its ability to continue as a going concern depends on increasing revenue, controlling costs, and obtaining external financing for new opportunities. The company plans to address material weaknesses in internal controls by hiring personnel with appropriate accounting knowledge, providing training, and potentially engaging a consulting firm, with partial implementation expected by the end of fiscal year 2026. ### Related Stocks - [ATPC.US](https://longbridge.com/en/quote/ATPC.US.md) ## Related News & Research - [06:31 ETNetherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight](https://longbridge.com/en/news/286895360.md) - [Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy | AVAI Stock News](https://longbridge.com/en/news/287067719.md) - [CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference](https://longbridge.com/en/news/287144135.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md) - [KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy](https://longbridge.com/en/news/287059695.md)